Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Clinical trial NCT06901622 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06901622
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-08
- Primary completion
- 2026-03-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.